Ajanta Pharma Limited, has received final approval for Duloxetine Hydrochloride Delayed Release Capsules from United States Food & Drug Administration (US FDA). It is a bioequivalent generic version of Cymbaltaź1 Delayed Release Capsules. Company will be launching the product shortly in 3 strengths, 20 mg, 30 mg and 60 mg strengths capsules.
Duloxetine Hydrochloride Delayed Release Capsules is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 32 Abbreviated New Drug Application (ANDA) of which it has 17 final ANDA approvals, 2 tentative approvals and 13 ANDAs under review with US FDA.
1 Cymbaltaź is a registered trademark of Eli Lilly And Co.
Shares of AJANTA PHARMA LTD. was last trading in BSE at Rs.1774.1 as compared to the previous close of Rs. 1794.05. The total number of shares traded during the day was 11326 in over 1503 trades.
The stock hit an intraday high of Rs. 1807.95 and intraday low of 1761.6. The net turnover during the day was Rs. 20171547.